Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trialsThe Lancet (British edition), 2022-02, Vol.399 (10326), p.741-755 [Peer Reviewed Journal]2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00018-6 ;PMID: 35085503Full text available |
|
2 |
Material Type: Article
|
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular EdemaAmerican journal of ophthalmology, 2022-06, Vol.238, p.157-172 [Peer Reviewed Journal]2022 ;Copyright © 2022. Published by Elsevier Inc. ;Copyright Elsevier Limited Jun 2022 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2022.01.004 ;PMID: 35038415Full text available |
|
3 |
Material Type: Article
|
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaThe New England journal of medicine, 2015-03, Vol.372 (13), p.1193-1203 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;Copyright © 2015 Massachusetts Medical Society. 2015 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414264 ;PMID: 25692915Full text available |
|
4 |
Material Type: Article
|
Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical TrialArchives of ophthalmology (1960), 2021-07, Vol.139 (7), p.701 [Peer Reviewed Journal]Copyright American Medical Association Jul 2021 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2021.0606Full text available |
|
5 |
Material Type: Article
|
Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I DataAmerican journal of ophthalmology, 2016-12, Vol.172, p.72-79 [Peer Reviewed Journal]2016 The Authors ;Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Dec 01, 2016 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2016.09.012 ;PMID: 27644589 ;CODEN: AJOPAAFull text available |
|
6 |
Material Type: Article
|
Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working GroupEye (London), 2020-06, Vol.34 (Suppl 1), p.1-51 [Peer Reviewed Journal]The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2020. ;The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2020 ;ISSN: 0950-222X ;EISSN: 1476-5454 ;DOI: 10.1038/s41433-020-0961-6 ;PMID: 32504038Full text available |
|
7 |
Material Type: Article
|
Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyesBritish journal of ophthalmology, 2021-02, Vol.105 (2), p.216-221 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2020-315933 ;PMID: 32265201Full text available |
|
8 |
Material Type: Article
|
Association of Ultra-Widefield Fluorescein Angiography–Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over TimeArchives of ophthalmology (1960), 2022-10, Vol.140 (10), p.936 [Peer Reviewed Journal]Copyright American Medical Association Oct 2022 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2022.3130Full text available |
|
9 |
Material Type: Article
|
Long-Term Visual Outcomes and Morphologic Biomarkers of Vision Loss in Eyes With Diabetic Macular Edema Treated With Anti-VEGF TherapyAmerican journal of ophthalmology, 2022-03, Vol.235, p.80-89 [Peer Reviewed Journal]2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021. Elsevier Inc. ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2021.09.002 ;PMID: 34509431Full text available |
|
10 |
Material Type: Article
|
Association of Statin Therapy With Prevention of Vision-Threatening Diabetic RetinopathyArchives of ophthalmology (1960), 2019-04, Vol.137 (4), p.363 [Peer Reviewed Journal]Copyright American Medical Association Apr 2019 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2018.6399Full text available |
|
11 |
Material Type: Article
|
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNVBritish journal of ophthalmology, 2017-03, Vol.101 (3), p.353-359 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/2017This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0 ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2016-308668 ;PMID: 27215744Full text available |
|
12 |
Material Type: Article
|
Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol TAmerican journal of ophthalmology, 2018-11, Vol.195, p.93-100 [Peer Reviewed Journal]2018 Elsevier Inc. ;Copyright © 2018 Elsevier Inc. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Nov 2018 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.07.030 ;PMID: 30077569Full text available |
|
13 |
Material Type: Article
|
Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti–Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical TrialArchives of ophthalmology (1960), 2019-04, Vol.137 (4), p.382 [Peer Reviewed Journal]Copyright American Medical Association Apr 2019 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2018.6786Full text available |
|
14 |
Material Type: Article
|
Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial SettingAmerican journal of ophthalmology, 2021-12, Vol.232, p.90-97 [Peer Reviewed Journal]2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021. Elsevier Inc. ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2021.06.030 ;PMID: 34283986Full text available |
|
15 |
Material Type: Article
|
Effects of Crocin on Diabetic Maculopathy: A Placebo-Controlled Randomized Clinical TrialAmerican journal of ophthalmology, 2018-06, Vol.190, p.89-98 [Peer Reviewed Journal]2018 Elsevier Inc. ;Copyright © 2018 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 2018 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.03.007 ;PMID: 29550187Full text available |
|
16 |
Material Type: Article
|
Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular EdemaAmerican journal of ophthalmology, 2016-04, Vol.164, p.57-68 [Peer Reviewed Journal]Elsevier Inc. ;2016 Elsevier Inc. ;Copyright © 2016 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Apr 2016 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2015.12.025 ;PMID: 26802783 ;CODEN: AJOPAAFull text available |
|
17 |
Material Type: Article
|
Next-generation anti-VEGF agents for diabetic macular oedemaEye (London), 2022-02, Vol.36 (2), p.273-277 [Peer Reviewed Journal]2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists. ;The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021. ;The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021 ;ISSN: 0950-222X ;EISSN: 1476-5454 ;DOI: 10.1038/s41433-021-01722-8 ;PMID: 34373607Full text available |
|
18 |
Material Type: Article
|
Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countriesBritish journal of ophthalmology, 2019-08, Vol.103 (8), p.1072-1077 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2018-312284 ;PMID: 30242062Full text available |
|
19 |
Material Type: Article
|
Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE StudyAmerican journal of ophthalmology, 2017-08, Vol.180, p.110-116 [Peer Reviewed Journal]2017 Elsevier Inc. ;Copyright © 2017 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Aug 1, 2017 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2017.05.024 ;PMID: 28579062Full text available |
|
20 |
Material Type: Article
|
Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical PracticeAmerican journal of ophthalmology, 2018-07, Vol.191, p.83-91 [Peer Reviewed Journal]2018 The Authors ;Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jul 2018 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.04.010 ;PMID: 29684329Full text available |